These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The utility of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma. Macapinlac HA Mol Imaging Biol; 2004; 6(4):200-7. PubMed ID: 15262235 [TBL] [Abstract][Full Text] [Related]
13. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125. Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509 [TBL] [Abstract][Full Text] [Related]
14. F-18 FDG PET/CT in the management of thyroid cancer. Iagaru A; Kalinyak JE; McDougall IR Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020 [TBL] [Abstract][Full Text] [Related]
15. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438 [TBL] [Abstract][Full Text] [Related]
17. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374 [TBL] [Abstract][Full Text] [Related]
18. Impact of 2-deoxy-2[F-18]fluoro-D-glucose Positron Emission Tomography on the management of patients with advanced melanoma. Harris MT; Berlangieri SU; Cebon JS; Davis ID; Scott AM Mol Imaging Biol; 2005; 7(4):304-8. PubMed ID: 16041590 [TBL] [Abstract][Full Text] [Related]
19. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. Gritters LS; Francis IR; Zasadny KR; Wahl RL J Nucl Med; 1993 Sep; 34(9):1420-7. PubMed ID: 8355058 [TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. Wong TZ; Jones EL; Coleman RE Mol Imaging Biol; 2004; 6(1):55-62. PubMed ID: 15018829 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]